Multi-omics analysis of genetic drivers linking aortic stenosis and left ventricular diastolic dysfunction in heart
Zeeshan Ahmed1,2, Prithvi Govindareddy3, Jayden Mathew3
1Division of Cardiovascular Diseases and Hypertension, Department of Medicine, Robert Wood Johnson Medical School, Rutgers Health, 125 Paterson St, New Brunswick, NJ, 08901, USA. zahmed@ifh.rutgers.edu.
Insights
Aortic stenosis and left ventricular diastolic dysfunction share genetic links in heart failure patients. Blood multi-omics can reveal early molecular signals for better diagnosis and treatment.
Area of Science:
- Genomics
- Cardiovascular Medicine
- Bioinformatics
Background:
- Aortic stenosis (AS) and left ventricular diastolic dysfunction (LVDD) frequently coexist in heart failure (HF), with unclear underlying mechanisms.
- While AS increases afterload, evidence suggests LVDD may precede or coincide with AS, pointing to shared inflammatory and mechanobiological drivers.
- This study investigates the genetic connections between AS and LVDD to identify early molecular markers and convergent pathways in HF.
Purpose of the Study:
- To explore genetic contributors linking aortic stenosis and left ventricular diastolic dysfunction in heart failure.
- To identify early molecular markers and convergent biological pathways shared by AS and LVDD.
- To investigate the genomic basis of co-occurring cardiovascular conditions.
Main Methods:
- Analysis of Whole Genome Sequence (WGS) and RNA-seq data from Peripheral Blood Mononuclear Cells (PBMCs) of heart failure patients.
- Utilized peer-reviewed, open-source pipelines for processing Next-Generation Sequence (NGS) data, including gene variant annotation and gene expression analysis.
- Performed bioinformatics and statistical analyses to identify genetic variations, expression patterns, regulation, enrichments, and disease associations.
Main Results:
- Identified unique and shared genetic markers associated with AS and LVDD.
- Reported genes with significant expression and functional variations, linking them to various cardiovascular and non-cardiovascular diseases, including cancers and rare genetic disorders.
- Validated findings using literature, gene-disease databases, and electronic health records.
Conclusions:
- AS and LVDD exhibit shared clinical and genomic associations, driven by overlapping genetic factors in inflammation, extracellular matrix remodeling, and vascular stress pathways.
- Blood-based multi-omics profiling shows promise for detecting early systemic molecular signals of cardiac dysfunction.
- This research provides a foundation for future tissue-specific studies to enhance precision diagnosis, risk stratification, and targeted therapies for HF.
Background:
Aortic stenosis (AS) and left ventricular diastolic dysfunction (LVDD) often coexist in heart failure (HF), but the mechanisms linking them remain unclear. While AS increases afterload and promotes myocardial stiffening, emerging AI-based evidence suggests LVDD can precede the development of AS or progress simultaneously, indicating shared upstream mechanobiological and inflammatory drivers. This study explores the genetic contributors connecting AS and LVDD to identify early molecular markers and convergent pathways in HF.
Method:
We analyzed Whole Genome Sequence (WGS) and RNA-seq data of the HF patients, generated using their Peripheral Blood Mononuclear Cells (PBMCs) samples. Overall bioinformatics analysis was divided into two modules, 1) gene variant and annotation analysis, and 2) gene expression and enrichment analysis. We utilized our peer review published and open source WGS and RNA-seq pipelines to process Next-Generation Sequence (NGS) data. Furthermore, we performed bioinformatics and statistical analysis to identify genetic variations, expressions, regulation, enrichments, and disease annotations.
Results:
We identified genetic markers uniquely associated with AS, LVDD, and shared between them. Furthermore, we report genes with significant expression, and functional variations, and discuss their relationship with other cardiovascular diseases (e.g. Vascular and Cardiac Stiffness, Aortic Dissection, Left Atrial Enlargement, Left Ventricular Hypertrophy, Outflow Tract Obstructive Defects, Non-Compaction Coronary Artery Disease, Arrhythmia, Congestive Heart Failure, and Hypertrophic, Dilated, and Ischemic Cardiomyopathy) and non-cardiovascular diseases (non-CVDs) (e.g. Type 1 Diabetes, Diabetic Nephropathy, Skeletal Anomalies, Rheumatoid Arthritis, Atypical Femoral Fractures, Chronic Kidney Disease, Dehydrated Hereditary Stomatocytosis, Schizophrenia, Varicose Veins, High-Altitude Pulmonary Edema, Periodontitis, and Respiratory Disorder) including multiple cancer types (e.g. Breast, Lung, Colorectal, Pancreatic, Hypopharyngeal, Acute Lymphoblastic, and Oral Squamous Cell Carcinomas) and rare genetic disorders (e.g. Hypophosphatasia, Multiple Sclerosis, Campomelic Dysplasia, Lymphatic Malformation). We validated our results through state of science literature, gene-disease annotation databases, and electronic health records.
Conclusions:
AS and LVDD share both clinical and genomic associations, with overlapping genetic drivers that are enriched in pathways related to inflammation, extracellular matrix remodeling, and vascular stress responses. This work supports the potential of blood-based multi-omics profiling to uncover early, systemic molecular signals of cardiac dysfunction and lays the groundwork for future tissue-specific studies to guide precision diagnosis, risk stratification, and targeted therapeutics in HF.
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure
Mitral Stenosis I: Introduction
Coronary Artery Disease II: Pathophysiology

